Clinical trials: Cancer Of Prostate
Prostate Cancer, Cancer
Adaptation of the American Cancer Society (ACS) Early Detection of Prostate Cancer Patient Decision Aid for Spanish Speaking Men
Objectives: The primary objective of this project is to develop and evaluate a Spanish-language slide set for administration in group settings, adapted from the content of the current guidelines and existing, self-administered…
- Trial name
- NCT01447186
- Testing
- Post-Test Questionnaire, Interviews, Focus Groups
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Reduced Planning Target Volume (PTV) Margins for the Treatment of Prostate Cancer Using the Calypso 4D Localization System
This prospective study evaluates the clinical utility of a novel real-time localization system allowing for smaller volumes of normal tissue to be included in radiation field and determines dosimetric parameters and adverse…
- Trial name
- PTV (NCT01589939)
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research Acquisition Activity
Prostate Cancer
Cultured Circulating Tumor Cells in Prostate and Other Cancers
The purpose of this study is to evaluate the number of circulating tumor cells (CTC) before and after treatment using an experimental method for detecting CTC, compared to commercial CTC assay results, in patients with prostate…
- Trial name
- NCT02123862
- Where
- United States
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Oscar Goodman, Jr.
Prostate Cancer
A Randomized Trial of Early Detection of Clinically Significant Prostate Cancer (ProScreen)
A population-based randomised trial of prostate cancer screening will be carried out. A total of approximately 117,200 men aged 50-63 in Helsinki and Tampere are randomised to intervention (screening) or control arm.
- Trial name
- ProScreen (NCT03423303)
- Testing
- Prostate cancer screening
- Where
- 2 sites in Finland
- Volunteers
- 17,400 people, healthy volunteers welcome
- Sponsor
- Tampere University
Prostate Cancer
Randomized Study Comparing MR-guided in Bore Versus MRI/US Fusion-guided Prostate Biopsy
The hypothesis of the study is that targeted MRI/US fusion-guided prostate biopsy with additional systematic transrectal ultrasound (TRUS)-guided biopsy significantly detects more prostate cancers than targeted MR-guided in-bore…
- Trial name
- NCT02220517
- Testing
- MR-guided in-bore prostate biopsy, MRI/US fusion-guided prostate biopsy
- Where
- Germany
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Heinrich-Heine University, Duesseldorf
Prostate Adenocarcinoma
Feasibility of Patient-Centered Home Care (PCHC) to Reduce Disparities in High-Risk Black Men (BM) With Prostate Cancer (CaP)
This study evaluates the possibility of patient-centered home care as a new model of cancer care to reduce disparities and improve health related quality of life and patient-reported outcomes in Black patients with prostate…
- Trial name
- NCT06470750
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Bladder Cancer, Glioma
Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer
The objective of this study is to assess two novel positron emission tomography (PET) radiotracers, [64Cu]CM500 and [68Ga]CM500, for Positron Emission Tomography-Magnetic Resonance Imaging (PET-MR) and Positron Emission…
- Conditions
- Bladder Cancer, Glioma, Glioblastoma (GBM), Breast Cancer
- Trial name
- NCT07781852
- Testing
- [64Cu]CM500, [68Ga]CM500, PET/MR
- Where
- 3 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Lumina Pharmaceuticals Inc
Prostate Cancer
Artificial Intelligence (AI)-Assisted Risk-based Prostate Cancer Detection
This is a prospective clinical study recruiting 510 men at risk of PCa to undergo urine, blood, AI-assisted ultrasound and AI-assisted MRI investigations to stratify risk of clinically significant PCa (csPCa).
- Trial name
- NCT05443412
- Testing
- Diagnostic test for prostate cancer
- Where
- Hong Kong
- Volunteers
- 510 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Inherited Cancer Syndrome, Prostate Cancer
Improving Care After Inherited Cancer Testing
The IMPACT Study seeks to refine and evaluate the effectiveness of interventions on improving guideline-adherent cancer risk management (CRM) and family communication (FC) of genetic test results for individuals with a documented…
- Conditions
- Inherited Cancer Syndrome, Prostate Cancer, Colorectal Cancer, Endometrial Cancer
- Trial name
- IMPACT (NCT04763915)
- Testing
- Correlative Studies (Survey), Correlative Studies (Interview), GeneSHARE
- Where
- United States
- Volunteers
- 720 people, healthy volunteers welcome
- Sponsor
- Vanderbilt-Ingram Cancer Center
Prostate Cancer
Evaluation of an MRI-based Prostate Cancer Screening Program (VISIONING): 5-Year Follow-up Round (VISIONING III)
Prostate cancer remains one of the leading causes of cancer-related morbidity and mortality among men. While PSA-based screening has been associated with reduced prostate cancer mortality, it also results in substantial…
- Trial name
- Visioning III (NCT07762911)
- Testing
- MRI
- Where
- Switzerland
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Prostate Cancer, MRI
NEWPROMRI-PATHWAY - A New Prostate Magnetic Resonance Imaging (MRI) Pathway
Prostate cancer is the second most common cancer in men worldwide. The demand for magnetic resonance imaging (MRI) to diagnose and manage prostate cancer is continually growing.
- Trial name
- NEWPROMRI (NCT06672926)
- Where
- United Kingdom
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- University Hospitals of North Midlands NHS Trust
Prostate Cancer
S0000 Selenium and Vitamin E in Preventing Prostate Cancer
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. It is not yet known which regimen of selenium and/or vitamin E may be more effective in preventing prostate cancer.
- Trial name
- SELECT (NCT00006392)
- Testing
- Vitamin E, Selenium
- Where
- 13 sites in United States
- Volunteers
- 35,533 people, healthy volunteers welcome
- Sponsor
- SWOG Cancer Research Network
Prostate Cancer
Predictive Value of Prostate-specific Antigen Isoform p2psa and Its Derivates in the Diagnosis of Prostate Cancer
In Europe, prostate cancer (PCa) is the most common solid neoplasm, with an incidence rate of 214 cases per 1000 men, outnumbering lung and colorectal cancer.
- Trial name
- NCT01672411
- Where
- Italy
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- University Of Perugia
Prostate Cancer
Diet, Genetic Variation and Prostate Cancer Among African Americans
This is a single center pilot study to asses the feasibility of conducting a larger population-based study. It is an investigator-initiated study funded yb the UC Davis Cancer Center's Development Award Program.
- Trial name
- NCT00584792
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Prostate Cancer
Lycopene or Green Tea for Men at Risk of Prostate Cancer
RATIONALE: Lycopene and green tea may stop or delay the development of recurrent prostate cancer in patients has been treated for prostate cancer.
- Trial name
- ProDiet (NCT01105338)
- Testing
- Green tea drink, green tea capsules, Lycopene capsules
- Where
- United Kingdom
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- University of Bristol
Prostate Cancer
Evaluation of a Web-based Decision Aid Tool for Prostate Cancer Patients
Patients diagnosed with localized prostate cancer may be eligible for different treatment options. MAASTRO Clinic (MAAStricht Radiation Oncology) developed a web-based decision aid tool for these patients.
- Trial name
- ProDecA (NCT03278197)
- Testing
- Interviews, Treatmentchoice Decisional Tool, Questionnaires
- Where
- Netherlands
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Maastricht Radiation Oncology
Prostate Cancer
Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc
This trial tests if the combination of comprehensive metastasis directed therapy delivered by a precision form of external beam radiotherapy (stereotactic ablative radiotherapy), combined with PSMA targeted radiopharmaceutical…
- Trial name
- NCT06084338
- Testing
- stereotactic ablative radiotherapy, Pluvicto, topical testosterone
- Where
- 4 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Prostate Cancer (Adenocarcinoma), Prostate Biopsy
RegisterPROS - A Registry for Prostate Cancers
Prostate cancers are derived from epithelial cells in the prostate gland. Treatment options include surgery, medical (androgen signaling targeted and chemotherapy) and radiation therapy including radioligand therapy (RLT).
- Conditions
- Prostate Cancer (Adenocarcinoma), Prostate Biopsy, Prostatectomy, Radioligand
- Trial name
- RegisterPROS (NCT06872619)
- Testing
- PROSTest
- Where
- Germany
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Wren Laboratories LLC
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Ann Arbor Stage I Lymphoma, Ann Arbor Stage II Lymphoma
- Trial name
- NCT05334069
- Testing
- Questionnaire Administration, Biospecimen Collection
- Where
- 751 sites in United States
- Volunteers
- 2,900 people, healthy volunteers welcome
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostate Cancer
Screening for Prostate Cancer Among Those Prostate-specific Antigen Value Between 2.5 and 4.0 ng/mL
The study aims to evaluate the detection rate and characteristics of prostate cancer among males with PSA values between 2.5 and 4.0 ng/mL in Nanjing, meanwhile, to access the effectiveness of conducting multi-parametric MRI…
- Trial name
- NCT04317625
- Testing
- mpMRI scanning
- Where
- China
- Volunteers
- 232 people, healthy volunteers welcome
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School